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SCI E N T I F I C IN V ESTI GATI ONS

Vitamin D Improves Selected Metabolic Parameters but not
Neuropsychological or Quality of Life Indices in OSA: A Pilot Study
Conor P. Kerley, PhD1,2; Katrina Hutchinson, MD3,4; Jessica Bramham, PhD5; Aisling McGowan, MSc1; John Faul, MD1; Liam Cormican, MD1
Respiratory and Sleep Diagnostics Department, Connolly Hospital, Blanchardstown, Dublin, Ireland; 2School of Medicine and Medical Sciences, University College Dublin,
Belfield, Dublin, Ireland; 3Biomnis Ireland, Sandyford Business Estate, Dublin, Ireland; 4NCBES, NUI Galway, Ireland; 5School of Psychology, University College, Dublin, Belfield,
Dublin, Ireland
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Study Objectives: Our group and others have reported a high rate of vitamin D deficiency in obstructive sleep apnea (OSA), where vitamin D levels (25(OH)
D) correlate negatively with OSA severity and some of its associated metabolic alterations. Data regarding vitamin D supplementation in OSA are lacking. We
wanted to evaluate the effect of vitamin D3 supplementation on OSA symptoms and metabolic parameters.
Methods: We conducted a pilot, double-blind, randomized, placebo-controlled trial of daily supplementation with 4,000 IU vitamin D3 (D3) or placebo
(PL). We studied 19 Caucasian adults (14 male, mean age 55 y, mean body mass index [BMI] 30.4 kg/m2) with OSA. Fifteen patients were stable on
continuous positive airways pressure (CPAP) therapy, whereas four were CPAP naïve. Assessments were completed at baseline and after 15 weeks of
supplementation. Outcomes included sleepiness (Epworth Sleepiness Scale), quality of life (Sleep Apnea Quality of Life Inventory), fatigue (fatigue severity
scale) and neuropsychological function (trail making test and Connor’s Continuous Performance Test II). In addition, we assessed biochemical indices of
vitamin D status (25(OH)D, calcium), inflammation (high sensitivity C-reactive protein, and lipoprotein-associated phospholipase A2), lipids (total cholesterol
[low-density and high-density lipoprotein]) and glycemic indices (fasting glucose, oral glucose tolerance test).
Results: There was no change in BMI, medication, or CPAP usage. Although there was no change in neuropsychological or quality of life indices, we
observed a significant increase in 25(OH)D (p = 0.00001) and significant decreases in both low-density lipoprotein (p = 0.04) and lipoprotein-associated
phospholipase A2 (p = 0.037) as well as trends toward decreased fasting glucose (p = 0.09) and increased high-density lipoprotein (p = 0.07) in the D3 group
compared to PL.
Conclusions: Vitamin D3 supplementation increased vitamin D levels and decreased metabolic markers compared to placebo. Larger trials are required.
Keywords: inflammation; lipids; obstructive sleep apnea; vitamin D
Citation: Kerley CP, Hutchinson K, Bramham J, McGowan A, Faul J, Cormican L. Vitamin D Improves selected metabolic parameters but not
neuropsychological or quality of life indices in OSA: a pilot study. J Clin Sleep Med. 2017;13(1):XXX–XXX.

I N T RO D U C T I O N

BRIEF SUMMARY

Current Knowledge/Study Rationale: Low vitamin D levels are
common in subjects with obstructive sleep apnea and correlate
with multiple cardiometabolic parameters. There is evidence the
supplementing with vitamin D may improve several physiological,
biochemical and subjective features of obstructive sleep apnea.
Study Impact: We present the first report of vitamin D
supplementation in obstructive sleep apnea where 15 weeks of daily
vitamin D supplementation at 4,000 IU/day decreased low-density
lipoprotein cholesterol and systemic inflammation (lipoproteinassociated phospholipase A2). Our pilot study is limited by small
sample size and heterogeneous study sample, but may serve to
increase knowledge and work in this area.

Obstructive sleep apnea (OSA) is strongly associated with obesity, which is reported in up to 70% of cases. OSA incidence
and/or severity is also related to ethnicity,1 winter season,2,3
and lack of physical activity.4 Additionally, OSA has been associated with multiple metabolic disturbances including excess systemic inflammation, hyperglycemia, hyperlipidemia,
cardiovascular disease, and increased bone loss.5
Vitamin D could, at least partially, mediate these relationships. Indeed, recently there has been interest in the idea that
vitamin D could be important for sleep disorders.6–8 A recent
study suggested that the association between lower 25(OH)
D and OSA was largely confounded by larger BMI and neck
circumference.9 In contrast, our group10 and others11–14 have
reported a high rate of vitamin D deficiency in OSA, where
vitamin D levels (25(OH)D) are lower in severe OSA10,11,13 and
inversely correlate with some of its associated metabolic alterations, including abnormal glucose metabolism11,12 as well
as nocturnal heart rate.10 Vitamin D receptors are located
systemically and recent advances have demonstrated the potential of vitamin D to influence a wide variety of organs.15

There is preliminary evidence that vitamin D supplementation may attenuate some metabolic disturbances through antiinflammatory, antihyperglycemic, and antihyperlipidemic
roles, although these potential effects are inconsistent and
controversial.
A recent comprehensive review regarding the link between
vitamin D metabolism and sleep medicine concluded that controlled studies are needed to further explore the relationship
1
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Inclusion criteria included previous OSA diagnosis by
polysomnography (PSG), Caucasian race, and stable medical
regimen including with or without CPAP for 6 mo or longer.
Exclusion criteria included mixed sleep apnea, history of coronary artery disease or diabetes or hypoglycemic agents and
syndromes/therapy known to interfere with vitamin D metabolism, including inflammatory bowel disease, as well as renal/
liver diseases and use of anticonvulsants, multivitamins, or vitamin D. At baseline, trial information was provided and written informed consent was obtained.

Figure 1—Trial design.

Study Design
This pilot study was designed as a parallel, randomized, double-blind, placebo-controlled trial and involved two clinic visits (Figure 1). Recruitment occurred between November 2013
and January 2014, with follow-up 15 w later. All assessments
were conducted at both baseline and follow-up in an identical
manner at the same time of morning with the same researcher
(CPK). Further, all assessments were conducted in the same
windowless room with identical lighting and temperature conditions. Following completion of day 1 presupplementation
assessments, subjects were randomized to vitamin D3 (D3) or
placebo (PL) groups using an online randomization program.

Assessments
PSG was conducted on all study participants as previously
described.10 At each time point, subjects reported to our research facility after an overnight fast, had blood drawn, and
consumed 75 g of glucose. Next, a battery of self-report questionnaires was completed in the same order followed by neuropsychological testing and a second blood sample was taken
2 h after glucose ingestion (Figure 1). For those established
on CPAP, compliance data were downloaded at baseline and
endpoint. For those not established on CPAP, therapy was not
initiated during this study.
The battery of self-report questionnaires included validated
questionnaires regarding sleep quality sleepiness (Epworth
Sleepiness Scale), quality of life (Sleep Apnea Quality of Life
Inventory), fatigue (Fatigue Severity Scale), and mood (Beck
Depression Inventory).
The neuropsychological testing included trail-making forms
A and B and two subscales of the Repeatable Battery for the
Assessment of Neuropsychological Status (R-BANS) (semantic fluency and coding). Subjects also completed the computerized Conner’s Continuous Performance test. Additionally, all
participants completed the Wechsler test of adult reading at
baseline only.

*Assessments included: fasting blood drawn, oral glucose tolerance test,
Epworth Sleepiness Scale, Fatigue Severity Scale, Beck Depression
Inventory and neuropsychological testing (trail making forms A and
B, three subscales of Repeatable Battery for the Assessment of
Neuropsychological Status and Conner’s Continuous Performance test.
PL = placebo; D3 = vitamin D3

between inadequate vitamin D and daytime neurocognitive
impairment, OSA and associated morbidity, particularly cardiovascular disease.16 Further, vitamin D supplementation may
have roles regarding sleep quality,17 sleepiness,18,19 fatigue,20
poor mood,21 and neuropsychological function.22 In this context, it is noteworthy that a 2010 case study reported resolution
of hypersomnia following vitamin D supplementation in a vitamin D deficient, African American woman.18
To our knowledge, there are no reports regarding the effect of vitamin D supplementation in OSA. In this pilot study,
we examined the effect of short-term vitamin D supplementation among urban adults with OSA, in terms of quality
of life, neuropsychological function, and cardiovascular
biomarkers.

Biochemistry
Venous blood was analyzed locally for full blood count, glucose, hemoglobin A1c, and lipids (total cholesterol, low-density
lipoprotein [LDL], high-density lipoprotein [HDL], triglycerides). Additional blood was centrifuged with isolated serum aliquoted and frozen to −80°C until required for further analysis.
Circulating levels of total 25-hydroxyvitamin D (25(OH)D)
are considered the most reliable measure of overall vitamin D
status because they reflect vitamin D2 + D3 contributions from
all sources (i.e., diet, supplements, and sun exposure. 25(OH)

METHODS

Subjects/Study Population
This pilot intervention study was conducted at Connolly Hospital, Blanchardstown (Dublin 15, Ireland, latitude, 53°N) after
institutional review board approval.
Journal of Clinical Sleep Medicine, Vol. 13, No. 1, 2017

2

CP Kerley, K Hutchinson, J Bramham, et al. Vitamin D Improves Metabolic Indices in OSA.

D was measured using the Architect 25(OH)D chemiluminescent microparticle immunoassay (CMIA) with interassay coefficient of variation of 3.5% and functional sensitivity less than
20 nmol/L 25(OH)D, parathyroid hormone, insulin, high sensitivity C-reactive protein, and lipoprotein-associated phospholipase A2 (Lp-PLA2) were analyzed on Abbott Architect ci8200
instrument (Abbott Laboratories, Abbott Park, IL, USA). The
interassay coefficient of variation for these assays ranged between 1% and 5.6%. Lp-PLA2 activity was assessed using an
enzyme-linked immunoassay (PLAC test, diaDexus, Inc., San
Franciso, CA, USA). The range of detection is 10 – 400 nmol/
min/mL, with a clinical sensitivity less than 10 nmol/min/mL.
Low Lp-PLA2 activity is indicated with values of 151 nmol/
min/mL or less, with medium values falling between 152–194
nmol/min/mL and high values indicated by a result of 195
nmol/min/mL or higher.

These 26 subjects were recruited and completed baseline assessments. Of the 26, there were 7 dropouts for miscellaneous
reasons (Figure 1). Baseline demographics for the 19 subjects
who completed the study are presented in Table 1. The mean
pretreatment 25(OH)D level for all patients was 37.2 nmol/L
(range, 14.5 to 86.5 nmol/L) and there was no significant difference in baseline 25(OH)D levels between the PL and D3 groups.
Further, there were no significant differences regarding age,
BMI, sleepiness (Epworth Sleepiness Scale score), education
level, or reading score between the D3 and PL group; however,
there were more males in the PL group and more CPAP users
in the D3 group.
Throughout the study, there was no change in medication
or CPAP compliance in either group. In addition, there was no
change in dietary habit or use of medication, alcohol, tobacco,
or caffeine. Compliance with the supplements was high in both
groups (93%) and there were no adverse effects.
Results before and after supplementation and comparisons
between groups are displayed in Table 2 (biochemical indices), Table 3 (neuropsychological indices), and Table 4 (selfreported questionnaire scores).
There was a significant increase in 25(OH)D, which was accompanied by a significant decrease in LDL and Lp-PLA2 in
the vitamin D3 group compared to placebo. Additionally, there
was a trend toward decreased fasting glucose and increased
HDL in the D3 group (Table 2).
We did not detect any differences in neuropsychological indices (Table 3) or quality of life scores (Table 4), except significantly improved fatigue in the vitamin D group.

Supplements
At baseline, each subject was provided with a consecutively
numbered bottle containing 120 softgel capsules of vitamin
D3 (cholecalciferol) or identical placebo in a double-blind, randomized fashion. A physician not involved in data gathering
(JF) generated the allocation sequence, while a dietitian and
nutrition researcher enrolled subjects (CPK). Subjects were instructed to ingest one softgel daily with food. The vitamin D
dose was 4,000 IU daily, which corresponds to the tolerable
upper intake limit in Europe.
Diet, supplement use, and particularly exposure to ultraviolet B radiation contribute to vitamin D status. Therefore, we
conducted this trial at high latitude during winter season when
skin vitamin D synthesis is minimal. Further, we advised recruits not to change dietary/supplemental behaviors during the
trial. We assessed behavior relating to vitamin D status with
the VIDSun questionnaire at baseline and endpoint, which
contains questions relating to BMI, skin type, sun exposure,
and supplement use.23 Supplement compliance was assessed
with a diary and by counting the remaining softgels at the follow-up visit.

D I SCUS S I O N
To our knowledge, this is the first report of vitamin D supplementation in OSA. We investigated the effect of vitamin D3
supplementation (4,000 IU/day) for 15 w compared to placebo
among a small sample (n = 19) of urban, Caucasian adults with
definite OSA as diagnosed by PSG. Consistent with previous
studies9–14 we observed a high rate of vitamin D deficiency
(89%) in our small OSA cohort. In addition to significantly
increased 25(OH)D in the vitamin D supplementation group
(n = 10), there were significant reductions in both LDL and
Lp-PLA2 compared to placebo. Additionally, there was a trend
toward decreased fasting glucose and increased HDL in the
D3 group.
Interest in the potential role of vitamin D in sleep disorders
has grown recently.6–8 We and others have observed widespread vitamin D OSA.9–14 Interestingly, 25(OH)D levels have
been shown to be inversely correlated with OSA severity10,11,13
and with metabolic alterations associated with OSA, including
abnormal glucose metabolism11,12 and nocturnal heart rate.10
A 2014 meta-analysis concluded that “Patients with OSA
appear to have increased dyslipidemia (high total cholesterol,
LDL, TG, and low HDL).” 24 Further, a large 2015 cross-sectional study demonstrated an independent association between
OSA and elevated LDL.25 The association between OSA and
dyslipidemia may mediate some of the excess cardiovascular
morbidity and mortality risk associated with OSA. Further, a

Statistical Analysis
For this pilot study we did not conduct a sample size calculation. To our knowledge, this pilot study represents the only
vitamin D supplementation trial in OSA and therefore we
recruited a convenience sample to preliminary assess the effect, if any, of vitamin D3 supplementation in OSA. We used
two-tailed, unpaired t-tests to compare baseline demographics between the two groups. We used two-tailed, paired t-tests
to compare changes within groups and two-tailed, unpaired
t-tests to compare changes between groups. All analyses were
performed using a software package (SPSS, version 18; SPSS,
Inc., Chicago, IL). Results were expressed as mean ± standard
deviation. We defined statistical significance as p < 0.05.

R ES U LT S
We screened 97 adults attending sleep clinics of Connolly Hospital. Of these 97, 40 were eligible and 26 provided consent.
3
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Table 1—Baseline demographics.
Placebo
9

n
Age, y, mean ± SD (range)

52 ± 13 (32 to 68)

Males, n (%)
AHI, mean ± SD (range)

Vitamin D
10

8 (89)

6 (60)

37.3 ± 26.7 (8 to 86)

CPAP users, n (%)
Smoking status
Current, n
Ex-smoker, n
LLNS, n

56 ± 10 (42 to 71)

5 (55.6)

25.6 ± 22.1 (6 to 79)
9 (90)

0
3
6

2
3
5

p*
–
0.41
–
0.31
–
–
–
–

BMI, kg/m2, mean ± SD (range)
Healthy range, n
Overweight, n
Obese, n

32 ± 8 (23 to 49)
2
1
6

30 ± 4 (25 to 36)
1
4
5

0.49
–
–
–

ESS (0 to 24), mean ± SD (range)

10 ± 6 (1 to 19)

11 ± 5 (3 to 19)

0.76

Years of education, mean ± SD (range)
WTAR Reading score (0 to 50), mean ± SD (range)
Fitzpatrick skin type †
1, n
2, n
3, n
4, n
25(OH)D (nmol/L), mean ± SD (range)
VDD at baseline, n (%)

13 ± 3 (8 to 18)

12 ± 4 (7 to 17)

0.54

27 ± 12 (13 to 47)

31 ± 11 (12 to 45)

0.50

1
1
6
1

0
4
6
0

41.4 ± 22 (18.9 to 86.5)
7 (78)

33.4 ± 11.6 (14.5 to 47)
10 (100)

0.33
–

*p values derived from two-tailed, unpaired t-tests. † Fitzpatrick skin type derived from VIDSun questionnaire. AHI = apnea-hypopnea index; BMI = body
mass index; ESS = Epworth Sleepiness Scale; LLNN = lifelong non-smoker; SD = standard deviation; VDD = vitamin D deficient (defined as 5 < 0 nmol/L);
WTAR = Wechsler test of adult reading.

2014 mendelian randomization study concluded that interventions that increased HDL may have an effect on coronary artery disease, but that interventions that decrease LDL have a
stronger effect on coronary artery disease.26 CPAP represents
the current gold standard treatment option for OSA and results
in numerous biochemical and physiological benefits. However, the effect of CPAP on lipidemia is controversial. Two
2014 meta-analyses provided conflicting evidence. One metaanalysis concluded that “treatment for OSA seems to improve
dyslipidemia (decrease in total cholesterol and LDL, and increase in HDL).” 27 However, a second meta-analysis concluded
that “CPAP did not alter TG, LDL, or HDL levels, suggesting
that CPAP may have no clinically important effect on lipid metabolism.” 28 Therefore, non-CPAP approaches to lipid lowering in OSA are warranted. Although the association between
vitamin D and cholesterol profiles is controversial, previous
reports have demonstrated significantly negative correlations
between serum LDL cholesterol and 25(OH)D.29–31 We provide
evidence that vitamin D3 supplementation can modestly but
significantly decrease serum LDL while maintaining serum
HDL concentration in OSA over a 15 w period with no change
in lifestyle or dietary intake. There was only a single subject
on lipid-lowering therapy (Atorvastatin) in this pilot study.
Interestingly, vitamin D supplementation decreased both total and LDL cholesterol in this subject (−0.3 and −0.44 mmol,
Journal of Clinical Sleep Medicine, Vol. 13, No. 1, 2017

respectively) despite concurrent lipid-lowering therapy, which
can be expected to dilute any benefit.
Lp-PLA2 is a biomarker that may be viewed as a potential
link between the pathogenic effects of oxidized LDL cholesterol and plaque vulnerability. Although there is a lack of data
regarding Lp-PLA2 and OSA, a recent cross-sectional study
of 50 male Turkish subjects with newly diagnosed OSA demonstrated a moderate linear relationship between arousal index
and Lp-PLA2 levels.32 Because the arousal index is an important index of sleep fragmentation and the restorative quality of
sleep, this association may contribute to the increased cardiovascular risk association with frequent arousal in OSA. Further, several epidemiology studies have shown an association
between Lp-PLA2 and both cardiovascular and cerebrovascular events. We are not aware of any reports linking vitamin
D and Lp-PLA2. The relationship between vitamin D and inflammation has been controversial. However, in vitro evidence
suggests that vitamin D has potent anti-inflammatory properties.33,34 Further, there are reports of decreased production of
several proinflammatory markers including tumor necrosis
factor-α, interferon γ, and interleukins 2,12,17, and 2,1 but increased production of anti-inflammatory interleukin-10 has
been reported with vitamin D supplementation in humans.34
Here, we observed a significant 19-point decrease in Lp-PLA2
after vitamin D3 supplementation compared to placebo.
4
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Table 2—Changes in biochemical indices.

25(OH)D (nmol/L)

Baseline
41.4 ± 22
(18.9 to 86.5)

Placebo
Endpoint
43.0 ± 21.4
(20.2 to 83.9)

Change
1.6

Baseline
33.4 ± 11.6
(14.5 to 47)

Vitamin D
Endpoint
Change
100.8 ± 39.9
67.4
(48.9 to 161.7)

p*
0.00001

Fasting glucose

5.4 ± 1.1
(4.3 to 7.3)

5.9 ± 1.9
(4.6 to 10.8)

0.5

6.7 ± 2.6
(3.9 to 12.2)

6.3 ± 2.3
(3.7 to 11.8)

−0.4

0.09

2 h blood glucose

7.8 ± 3.3
(4.8 to 13.2)

7.3 ± 2.7
(4.8 to 12.4)

−0.5

9.6 ± 4.1
(5.0 to 16.4)

7.1 ± 2.8
(4.5 to 12.2)

−2.5

0.23

0.1 ± 3.2
(−8.0 to 4.0)

−1.83

0.30

Glucose excursion

1.5 ± 3.6
(−6.0 to 6.3)

HbA1c

40.3 ± 8.7
(31.0 to 57.0)

38.4 ± 8.9
(30.0 to 51.0)

−1.9

51.7 ± 20.5
(35.0 to 90.0)

46.4 ± 17.0
(32.0 to 82.0)

−5.3

0.35

Insulin

19.3 ± 20.9
(6.6 to 69.0)

13.0 ± 10.4
(3.6 to 31.8)

−6.3

10.7 ± 3.9
(3.8 to 18.5)

11.6 ± 4.4
(3.6 to 16.9)

1.1

0.10

Total cholesterol

4.4 ± 1.1
(3.1 to 6.3)

4.2 ± 0.9
(3.3 to 5.9)

−0.2

4.6 ± 1.2
(2.8 to 6.2)

4.3 ± 0.9
(2.9 to 5.9)

−0.3

0.38

LDL

2.4 ± 0.8
(1.4 to 3.9)

2.5 ± 0.7
(1.7 to 3.9)

0.1

2.6 ± 0.9
(1.2 to 3.7)

2.3 ± 0.7
(1.6 to 3.8)

−0.3

0.04

HDL

1.2 ± 0.2
(0.9 to 1.7)

1.1 ± 0.1
(0.9 to 1.3)

−0.1

1.1 ± 0.3
(0.8 to 1.6)

1.1 ± 0.3
(0.7 to 1.5)

0.0

0.07

CRP

2.7 ± 2.7
(0.3 to 8.4)

2.5 ± 2.2
(0.1 to 7.0)

−0.2

4.7 ± 5.9
(0.1 to 18.5)

3.8 ± 3.8
(0.6 to 11.6)

−0.9

0.20

Lp-PLA2

0.6 ± 4.7
(−10.8 to 5.7)

−0.9

173.0 ± 33.6
172.0 ± 34.7
(100.0 to 207.0) (119.0 to 207.0)

−1.0

1.9 ± 5.6
(−12.2 to 6.8)

185.0 ± 42.0
166.0 ± 32.5 −19.0
(114.0 to 253.0) (111.0 to 202.0)

0.037

Data are presented as mean ± standard deviation (range). *p values derived from one-tailed, unpaired t-tests comparing the change after placebo to change
after vitamin D 3. 25(OH)D = 25-hydroxyvitamin D; CRP = C-reactive protein; HbA1c = glycated haemoglobin; HDL = high-density lipoprotein; LDL = lowdensity lipoprotein; Lp-PLA2 = lipoprotein-associated phospholipase A2; PTH = parathyroid hormone; TAG = triglycerides.

Table 3—Changes in neuropsychological indices.
Baseline
17 ± 3
(12 to 22)

Placebo
Endpoint
17 ± 34
(11 to 22)

Change
0

Baseline
18 ± 7
(11 to 34)

Vitamin D
Endpoint
18 ± 4
(13 to 24)

Coding

35 ± 16
(5 to 65)

41 ± 13
(24 to 68)

6

36 ± 12
(24 to 53)

Trail making A (sec)

35 ± 16
(22 to 72)

35 ± 18
(16 to 60)

0

Trail making B (sec)

89 ± 53
(33 to 209)

101 ± 52
(22 to 184)

CPT II Omission T-score

71 ± 53
(42 to 209)

CPT II Omission percentile

p*
Change
0

0.26

40 ± 13
(24 to 55)

4

0.10

33 ± 11
(16 to 54)

35 ± 13
(17 to 58)

2

0.40

11

97 ± 42
(32 to 175)

85 ± 36
(34 to 150)

−12

0.18

71. ± 45
(42 to 181)

0

74 ± 35
(40 to 143)

67 ± 22
(40 to 113)

−7

0.34

61 ± 32
(22 to 99)

65 ± 34
(22 to 99)

4

72 ± 30
(18 to 99)

77 ± 28
(18 to 99)

−5

0.85

CPT II Commission T-score

53 ± 13
(38 to 76)

48 ± 10
(33 to 59)

−5

72 ± 7
(42 to 60)

49 ± 8
(39 to 62)

−3

0.43

CPT II Commission percentile

58 ± 35
(13 to 99)

49 ± 32
(5 to 83)

−9

57 ± 24
(223 to 84)

49 ± 27
(15 to 89)

−8

0.88

Semantic fluency

Data are presented as mean ± standard deviation (range). *p values derived from one-tailed, unpaired t-tests comparing the change after placebo to change
after vitamin D3. CPT II = Conner’s Continuous Performance Test.

Patients with OSA demonstrate cognitive dysfunction both
subjectively and objectively.35 A recent comprehensive review
concluded that controlled studies are needed to further explore
the relation between inadequate vitamin D and daytime neurocognitive impairment in OSA.7 There is much interest in the

potential of vitamin D regarding cognition, with a recent metaanalysis demonstrating that low 25(OH)D predicts executive
dysfunctions, especially on mental shifting, information updating, and processing speed.35 It is has been suggested that
hypoxemia contributes more to cognitive dysfunction in OSA
5
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Table 4—Changes in self-reported questionnaire score.

ESS (0 to 24)

Baseline
10 ± 6
(1 to 19)

Placebo
Endpoint
7±5
(0 to 16)

Baseline
11 ± 5
(3 to 19)

Vitamin D
Endpoint
6±2
(3 to 11)

FSS (0 to 63)

46 ± 9
(29 to 58)

34 ± 8
(0 to 52)

−10

53 ± 7
(39 to 62)

38 ± 16
(0 to 57)

SAQLI total score (0 to 7)

0.5 ± 0.2
(0.3 to 0.7)

0.5 ± 0.2
(0.2 to 0.7)

0

1.5 ± 0.3
(1.1 to 2)

1.9 ± 0.4
(1.3 to 2.4)

VIDSun score (0 to 7)

2±1
(1 to 4)

2±1
(1 to 4)

0

3±1
(2 to 6)

2±1
(1 to 4)

−1

0.002

BDI (0 to 63)

16 ± 10
(1 to 37)

12 ± 9.8
(0 to 28)

−4

14 ± 7
(2 to 23)

12 ± 9
(0 to 27)

−2

0.46

Mean Change
−3

p*
Mean Change
−5
−14
0.4

0.90
0.31
0.08

Data are presented as mean ± standard deviation (range). *p values derived from two-tailed, unpaired t-tests comparing the change after placebo to change
after vitamin D3. BDI = Beck Depression Inventory; ESS = Epworth Sleepiness Scale; FSS = Fatigue Severity Scale; SAQLI = sleep apnea quality of life
inventory; VIDSun = vitamin D + Sun questionnaire.

than frequent arousals or daytime sleepiness.36 However, this
suggestion is controversial. Considering that 90% of the vitamin D supplementation group were CPAP users, any potential
benefit of vitamin D supplementation in OSA could have been
diluted. Therefore, although we performed very detailed neuropsychological assessments and observed no cognitive benefit
here, our small sample and the use of CPAP mean that this pilot
study cannot rule out a potential benefit of vitamin D supplementation in OSA.
Our pilot study has several strengths. We utilized the gold
standard study design and assessed objective, subjective, and
biochemical markers of OSA. We studied a well-characterized
group of urban, Caucasian adults with definite OSA. The placebo and vitamin D groups were well matched at baseline with
no significant differences in demographics. In the current study,
all patients were Caucasian and resided in Dublin, Ireland. All
of the 25(OH)D assays were conducted using the same batch
of commercial assays and were performed concomitantly by
the same biochemist in the same laboratory, thereby reducing
biochemical variability. Vitamin D trials can be influenced by
a number of factors, including fluctuations in sun exposure and
hence 25(OH)D levels, variable quality of vitamin D assays,
compliance with the intervention, and provision of inadequate
vitamin D supplementation doses. To overcome these factors,
we conducted this trial over the winter season at high latitude
(53°N) when vitamin D photosynthesis is minimal. Although
we purposely did not restrict nonprotocol dietary or supplemental vitamin D intake, we did ask that such behaviors were
not altered during the trial. Identical vitamin D behaviors were
evident in both groups throughout the trial as confirmed with
VIDSun scores. Compliance, as assessed by diary data and
capsule counts, was high (93%). We utilized a moderate-high
dose of vitamin D3 (4,000 IU/day). In unison with our trial design and high compliance with the supplements, serum 25(OH)
D increased significantly in the vitamin D3 group, but did not
change in the placebo group.
Our pilot study also has several important limitations. Although there was no difference in 25(OH)D levels at baseline, the mean 25(OH)D was higher in the placebo group.
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Twenty-two percent of subjects were vitamin D sufficient at
baseline, which is of note because supplementation appears
most beneficial to those with vitamin D deficiency. Further,
as expected all recruits in the intervention arm had increases
in 25(OH)D but three of the placebo group (33%) also experienced increases in 25(OH)D (+10 to +22 nmol/L). Although
we recruited an exclusively Caucasian sample, the sample was
very small (n = 19) and heterogeneous in terms of CPAP usage. However, we ensured that CPAP was neither commenced
nor discontinued throughout the trial. Further, we downloaded
CPAP compliance data at baseline and endpoint, observing the
CPAP usage did not change and ensuring that CPAP was carefully controlled during the study. An additional limitation is
the lack of a power calculation and primary endpoint. However,
the value of this pilot is to act as a hypothesis-generating basis
for future work. It is possible that the statistical significance of
our observations would be increased with a large sample size
and a more homogeneous population.

CO N CLU S I O N S
In conjunction with a significant increase in 25(OH)D levels,
this pilot study suggests that vitamin D supplementation has
the potential to improve relevant biomarkers of cardiometabolic health in OSA. It can be hypothesized that this effect
may translate into clinical benefit over the long term due to
decreased morbidity and mortality. Vitamin D replenishment warrants further investigation as an adjunct therapeutic
strategy in OSA.
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CPT II, Conner’s Continuous Performance Test
CRP, C-reactive protein
ESS, Epworth Sleepiness Scale
HbA1c, glycated haemoglobin
HDL, high density lipoprotein
LDL, low density lipoprotein
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LP-PLA2, lipoprotein-associated phospholipase A2
OSA, obstructive sleep apnoea
PSG, polysomnography
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SAQLI, sleep apnea quality of life inventory
TAG, triacylglycerol
VDD, vitamin D deficiency
VIDSun, vitamin D + Sun questionnaire
WTAR, Wechsler test of adult reading
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